Morgan Stanley: CSPC Pharmaceutical Group (01093.HK) 3Q Finished Drug Sales Slightly Beat Expectations, Multiple Pipeline Catalysts Expected
Zhitong Finance APP has learned that Morgan Stanley has issued a research report stating that CSPC Pharmaceutical Group (01093.HK) reported third-quarter finished drug sales slightly above expectations, with multiple pipeline catalysts ahead that reinforce the bank's investment thesis. The bank maintains its "Overweight" rating and target price of HK$12 for CSPC Pharmaceutical Group.
Latest

